FDA calls on companies to end marketing of unapproved suppositories

Share this article:
The FDA today asked five drugmakers to end the manufacturing and marketing of suppository drug products containing trimethobenzamide hydrochloride, due to lack of evidence of effectiveness. The products, used to treat nausea and vomiting in adults and children, have been marketed under various names including Tigan, Tebamide, T-Gen, Trimazide and Trimethobenz. The FDA is asking five manufacturers and six distributors of the unapproved suppositories to stop making and distributing them. The agency did not immediately identify the drug companies and distributors. Companies making or marketing trimethobenzamide hydrochloride suppository products must cease shipping them in interstate commerce by May 9, the FDA said. A small amount of these products will still be available in pharmacies until supplies are exhausted. After May 9, any company wishing to market a product containing trimethobenzamide in suppository form must obtain an approved New Drug Application prior to marketing, the agency said. If the companies and distributors do not comply, the government can seize the products and force the companies to stop making the drugs through a court order. The action is part of an ongoing FDA effort to pursue prescription drugs that do not have agency approval. Many of those unapproved drugs were on the market prior to a 1962 law requiring the agency to evaluate a drug’s safety and effectiveness before allowing it on the market. Earlier laws focused mainly on drug safety.
Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.